Mendeley出力
＜学術雑誌論文＞
A new mutation of congenital methemoglobinemia exacerbated after methylene blue treatment
| 作成者 | |
|---|---|
| 本文言語 | |
| 出版者 | |
| 発行日 | |
| 収録物名 | |
| 巻 | |
| 号 | |
| 開始ページ | |
| 終了ページ | |
| 出版タイプ | |
| アクセス権 | |
| 権利関係 | |
| 権利関係 | |
| 関連DOI | |
| 関連URI | |
| 関連HDL | |
| 概要 | Case: Methylene blue is useful for the treatment of methemoglobinemia. However, even after the patient's methemoglobin (metHb) rate has improved, careful observation is important because they could hav...e undiagnosed congenital methemoglobinemia. In this case, a 67-year-old man underwent gastrointestinal endoscopy with the use of lidocaine for local anesthesia. During the examination, he complained of dyspnea and had low SpO_2 despite normal PaO_2 and SaO_2. He was transferred to our department as a suspected case of acquired methemoglobinemia. Outcome: The patient's metHb level was 26.2%. We administered methylene blue i.v. and his metHb level subsequently decreased to 1.6%. However, his metHb level gradually increased to 18.2%, and we suspected that he had congenital methemoglobinemia. We administered riboflavin and ascorbic acid orally, and his metHb level decreased to 6.4%. We also obtained genomic DNA from the patient and identified a novel variant of CYB5R3. Conclusion: We report a novel variant of congenital methemoglobinemia that deteriorated after methylene blue treatment.続きを見る |
詳細
| PISSN | |
|---|---|
| EISSN | |
| レコードID | |
| 主題 | |
| タイプ | |
| 登録日 | 2024.12.25 |
| 更新日 | 2024.12.26 |